Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Safety profile of Endeavor drug-eluting coronary stent is revealed

Medtronic : 24 October, 2007  (New Product)
A pooled analysis of safety data from Medtronic’s Endeavor clinical programme has affirmed the superior safety of the Endeavor drug-eluting coronary stent compared to the best-in-class Medtronic bare metal stent, Driver.
The analysis was presented at the Cardiovascular Research Foundation’s annual TCT meeting.

The analysis illustrated that Endeavor (n=2,132), when compared to Driver (n=596), was associated with low rates of all evaluated safety metrics. For Endeavor the respective rates, cumulatively, at three years were: heart attack (2.7 per cent), Stent thrombosis (0.7 per cent), death (3.2 per cent) cardiac death (1.0 per cent).

For Driver, the rates were: heart attack (4.2 per cent), Stent thrombosis (1.5 per cent), death, (4.5 per cent), cardiac death (2.4 per cent). These results mirror those of ENDEAVOR II, a 1,200-patient randomised clinical trial which directly compared Endeavor to Driver.

In Endeavor II, the Endeavor Stent was associated with lower absolute rates of cardiac death, heart attack and Stent thrombosis in follow up to three years.

The results were not only indicative of comparable safety to a bare-metal stent, they were also consistent in more challenging patient groups. For patients with diabetes or complex lesions, for whom safety is an even greater concern, Endeavor was found to have performed at least as well as the bare-metal Stent across all measured safety metrics.

Laura Mauri, MD, MSc, chief scientific officer of the Harvard Clinical Research Institute, and interventional cardiologist at the Brigham and Women’s Hospital, the author of the analysis, said, “Many of today’s cardiologists are concerned about the safety of drug-eluting stents compared to their bare-metal precursors, which are considered a benchmark for long-term safety. We were encouraged to have concluded that the next-generation Endeavor drug-eluting Stent was associated with numerically fewer adverse events than the Driver bare-metal stent, itself a Stent noted for its performance and safety characteristics.”
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo